共 50 条
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
被引:497
|作者:
Ogitani, Yusuke
[1
]
Hagihara, Katsunobu
[2
]
Oitate, Masataka
[2
]
Naito, Hiroyuki
[3
]
Agatsuma, Toshinori
[1
]
机构:
[1] Daiichi Sankyo Co Ltd, Biol & Immunooncol Labs, Tokyo, Japan
[2] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan
[3] Daiichi Sankyo Co Ltd, Oncol Labs, Tokyo, Japan
关键词:
Antibody-drug conjugate;
bystander killing;
HER2;
T-DM;
topoisomerase I inhibitor;
BRENTUXIMAB VEDOTIN;
GEMTUZUMAB OZOGAMICIN;
TRASTUZUMAB EMTANSINE;
CATHEPSIN-B;
EXPRESSION;
LYMPHOMA;
THERAPY;
PHASE-3;
SAFETY;
D O I:
10.1111/cas.12966
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window. DS-8201a is a human epidermal growth factor receptor 2 (HER2)-targeting antibody-drug conjugate prepared using a novel linker-payload system with a potent topoisomerase I inhibitor, exatecan derivative (DX-8951 derivative, DXd). It was effective against trastuzumab emtansine (T-DM1)-insensitive patient-derived xenograft models with both high and low HER2 expression. In this study, the bystander killing effect of DS-8201a was evaluated and compared with that of T-DM1. We confirmed that the payload of DS-8201a, DXd (1), was highly membrane-permeable whereas that of T-DM1, Lys-SMCC-DM1, had a low level of permeability. Under a coculture condition of HER2-positive KPL-4 cells and negative MDA-MB-468 cells in vitro, DS-8201a killed both cells, whereas T-DM1 and an antibody-drug conjugate with a low permeable payload, anti-HER2-DXd (2), did not. In vivo evaluation was carried out using mice inoculated with a mixture of HER2-positive NCI-N87 cells and HER2-negative MDA-MB-468-Luc cells by using an in vivo imaging system. In vivo, DS-8201a reduced the luciferase signal of the mice, indicating suppression of the MDA-MB-468-Luc population; however, T-DM1 and anti-HER2-DXd (2) did not. Furthermore, it was confirmed that DS-8201a was not effective against MDA-MB-468-Luc tumors inoculated at the opposite side of the NCI-N87 tumor, suggesting that the bystander killing effect of DS-8201a is observed only in cells neighboring HER2-positive cells, indicating low concern in terms of systemic toxicity. These results indicated that DS-8201a has a potent bystander effect due to a highly membrane-permeable payload and is beneficial in treating tumors with HER2 heterogeneity that are unresponsive to T-DM1.
引用
收藏
页码:1039 / 1046
页数:8
相关论文